Funding Opportunities

Grants for melanoma and skin cancer clinical research

Melanoma and Skin Cancer Trials conducts investigator-initiated clinical trials and related research to improve how doctors prevent, diagnose and treat melanoma and skin cancer.

We have built an impressive reputation for delivering multicentre trials that improve melanoma and skin cancer outcomes across the world. Since 1999, we have delivered 29 clinical trials involving over 7,500 participants.

Melanoma and Skin Cancer Trials facilitates the development of competitive investigator-initiated proposals through our concept development pathway. For more information on how we can help you develop a research proposal and secure funding, contact us.

MRFF – 2026 Improving Health Interventions and Services through Implementation Research Grant Opportunity - GO8671

Open Date

21 October 2026

Closing Date

03 February 2027 (Minimum Data); 3 March 2027 (Full Application)

Grant amount

$5,000,000.00 AUD (Total Amount $20,000,000.00 AUD)

About

The objective of this grant opportunity is to provide grants of financial assistance to support medical research and medical innovation projects that:

Stream 1: Conduct co-designed proof of concept or pilot studies to generate evidence of feasibility, affordability, acceptability, and impact of implementation strategies.

Stream 2: Conduct small- or large-scale multidisciplinary implementation research focused on improving the adoption, sustainability, and/or scaling of evidence-based health and wellbeing interventions:

  • that are conducted in partnership with health service providers and consumers, and
  • focussed on one or more priority populations.

The intended outcome of the research funded by this grant opportunity is to improve the health and wellbeing of Australians by:

Stream 1: Building the evidence base for effective implementation of health interventions.

Stream 2: Improving the effectiveness and quality of health and wellbeing interventions and services through robust implementation research.

MRFF – Rapid Applied Research Translation Grant Opportunity - GO8672

Open Date

21 October 2026

Closing Date

10 February 2027 (Minimum Data); 10 March 2027 (Full Application)

Grant amount

$5,000,000.00 AUD (Total Amount $48,100,000.00 AUD)

About

The objective of this grant opportunity is to provide grants of financial assistance to support medical research and medical innovation projects that:

  • deliver late-stage translational research that is directly relevant to clinical care, health services and/or health practices, which has the potential to be translated into existing policy and practice
  • use existing knowledge and evidence to support and accelerate the translation of research findings into improved health care and health interventions
  • address a clearly defined gap in best practice health care and health interventions to improve health outcomes, as identified by collaborating health services
  • involve all stakeholders relevant to the research and its translation in its conceptualisation, design and implementation, including health care consumers and providers.

Two streams of funding are available:

Stream 1: The organisation undertaking the majority of the research can be in any location.

Stream 2: The organisation undertaking the majority of the research is in a regional, rural or remote area according to the Modified Monash Model (MM2-7). Also, the Chief Investigator A, at least 50% of all Chief Investigators, and all research participants must be primarily resident in a regional, rural or remote area.

MRFF – 2026 Research Data Infrastructure Grant Opportunity - GO8704

Open Date

4 November 2026

Closing Date

17 February 2027 (Minimum Data); 17 March 2027 (Full Application)

Grant amount

$2,500,000.00 AUD (Total Amount $30,000,000.00 AUD)

About

The objective of this grant opportunity is to provide grants of financial assistance to support medical research and medical innovation projects that use novel methods to harness multiple existing data infrastructure types in developing and implementing new approaches for addressing an unmet medical need.

The intended outcome of the research funded by this grant opportunity is to improve the health and wellbeing of Australians by supporting Australian medical research and medical innovation projects that use multiple types of existing research data infrastructure in new ways in areas of existing or emerging unmet health need.

MRFF – 2026 Clinical Trials Activity Grant Opportunity - GO8645

Open Date

30 September 2026

Closing Date

10 March 2027 (Minimum Data); 7 April 2027 (Full Application)

Grant amount

$5,000,000.00 AUD (Total Amount $136,000,000.00 AUD)

About

The Medical Research Future Fund (MRFF) Clinical Trials Activity Initiative aims to:

  • improve the evidence base supporting clinical care
  • help patients access trials relevant to their health circumstances
  • enable researchers to bring international trials to Australian patients.

The objective of this grant opportunity is to provide grants of financial assistance to support medical research and medical innovation projects that:

  • Stream 1 (Incubator): conduct a pilot study to assess the feasibility of a new clinical trial for one or more treatments and/or management strategies for a rare cancer, rare disease and/or unmet need.
  • Stream 2 (Targeted Call for Research): conduct a clinical trial of one or more treatments and/or management-based interventions for rare cancers, rare diseases and/or unmet need
  • Stream 3 (Targeted Call for Research): conduct a clinical trial that supports the delivery of effective and high value care by targeting evidence gaps of value to health technology assessment processes in Australia.
  • Stream 4 (Targeted Call for Research): conduct a prevention clinical trial aimed at reducing the risk, onset or progression of disease through early intervention strategies

Ideas Grants 2027

Open Date

03 February 2027

Closing Date

24 February 2027 (Minimum Data); 17 March 2027 (Full Application)

Grant amount

TBC

Application website

About

The objective of the Ideas Grant scheme is to support innovative research projects addressing a specific question(s).

The expected outcomes are:

  • innovative and creative research
  • funding of researchers at all career stages
  • funding any area of health and medical research from discovery to implementation.

The Ideas Grant scheme is not intended to support research where a clinical trial or cohort study is the primary objective. Applicants conducting projects which incorporate elements of clinical trial and/or cohort study must consider whether the project goals are more applicable to the Ideas Grant or Clinical Trials and Cohort Grant schemes.

International Grant Opportunities:

Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01 Clinical Trials Required) - RFA-FD-25-020

Open Date

22 August 2025

Closing Date

19 October 2027

Grant amount

The total funds available is up to: $2,600,000 USD

About

This grant is intended to support clinical trials of orphan products in all phases of product development (phase 1, 2 and/or 3) for rare diseases with unmet medical needs. These clinical trials should evaluate safety and/or efficacy of medical products in support of a new indication or a change in labeling. Depending on the phase of development, these trials may need to include an appropriate comparator, such as a placebo, a concurrent external control, or a historical control.  Applicants are encouraged to refer to “Rare Diseases: Considerations for the Development of Drugs and Biological Products” for guidance on conducting more efficient and successful drug development programs. Applicants are also encouraged to refer to Guidance Documents for Rare Disease Drug Development for selected guidances relevant to rare disease drug development and information on the Orphan Products Grants Program website before applying for this opportunity.

To facilitate efficient product development, the use of shared, established infrastructure and resources and collaborative efforts between stakeholders in industry, academia, and patient organizations are highly encouraged under this grant. Additionally, patients living with a rare disease, or their caregivers have experiences and knowledge that contribute to important considerations in product development, such as with trial feasibility, thus early and ongoing patient engagement is also highly encouraged.

Innovative and Efficient Trial Approaches:
FDA is interested in supporting innovative and efficient trial designs and will allow for additional funding with justification for applications proposing the use of one or more of the following:

  • Innovative trial designs such as seamless and adaptive trial designs, which compress the phases of a trial into one continuous trial, as well as basket, umbrella and platform trials, which allow for testing of multiple drugs and/or multiple diseases using a common infrastructure.
  • Innovative methods using data simulations and modeling toward the study of safety and efficacy of a product.

These approaches may hold significant promise for the advancement of therapeutic treatments for rare diseases through all phases of product development. Early engagement with FDA review divisions to discuss the use of these innovative approaches is highly recommended prior to submitting a grant application (e.g., preIND, INTERACT, other meetings).

Foreign Organizations
  • Non-domestic (non-U.S.) Entities (Foreign Organizations) are eligible to apply.
  • Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
  • Foreign components, as defined in the NIH Grants Policy Statement, are allowed.

CRI Clinical Innovator

Open Date

N/A

Closing Date

1 December 2026 (Protocol Concept); 1 April 2027 (Invited Full Proposal)

Grant amount

Up to $1,000,000 USD

Application website

About

The CRI Clinical Innovator funds innovative phase I/II or phase II clinical studies with a strong emphasis on:

  • Novel immunotherapy approaches
  • Mechanistic investigations into clinical response
  • The discovery and/or validation of predictive biomarkers

In an effort to maximize impact and ensure translational rigor, CRI may provide strategic guidance on trial design. CRI encourages data sharing through platforms such as the CRI iATLAS.

Applications are evaluated based on novelty, feasibility, scientific rationale, and potential for clinical impact. Competitive studies will integrate standardized approaches to sample collection, correlative assays, and advanced data analyses, ensuring that findings are reproducible, shareable, and impactful across the field.

By supporting clinician-scientists at the forefront of immunotherapy, the Clinical Innovator program advances clinical research that not only tests new therapies, but also deepens our understanding of the immune system’s role in cancer.

LifeArc Rare Disease Clinical Trials Programme

Open Date

22 August 2025

Closing Date

No formal deadline; EOI reviewed regularly

Grant amount

£5M per proposal

About

LifeArc aims to translate promising research into life-changing innovations for people living with rare diseases within 5 years. To help deliver this ambition, our Rare Disease Clinical Trials Programme exists to help progress potentially transformative rare disease innovations through clinical development.

The programme supports academic institutions and industry to deliver high-quality clinical data through early-stage clinical trials. These must focus on proof of efficacy, with consideration of the route to patient impact within 5 years. Interventions can include:

  • therapeutics (including repurposed drugs) and advanced therapies (including gene and cell therapies)
  • medical technologies or devices
  • diagnostics that demonstrate potential to improve decision-making and outcomes.

Melanoma Research Alliance (MRA) - 2026-2027 Request for Proposals

Open Date

13 July 2026

Closing Date

Application deadlines vary by award.

Grant amount

Up to $375,000 USD

Application website

About

MRA is soliciting proposals that address the gap in translational science (i.e., turning scientific
discoveries into tools and/or treatments for high-risk individuals and patients with melanoma).
Proposals for clinical studies testing well-defined and clearly articulated hypotheses are welcome.

MRA welcomes proposals in the following areas:

  • Detection and Diagnosis: Development of innovative detection and diagnostic methodologies; identification and validation of diagnostic and prognostic biomarkers.
  • Treatment: Projects emphasizing the translation of scientific findings to new treatments for
    patients with melanoma. Examples include, but are not limited to, studies of melanoma
    immunotherapy, therapeutic applications based on molecular mechanisms involved in
    melanoma formation and/or progression, treatments that target the tumor microenvironment or microbiome, combination therapies, and development of novel
    biomarkers of response to therapy.
  • Prevention: Elucidation of environmental, epidemiological, and biological factors in
    melanomagenesis that lead to improved strategies for melanoma prevention.

2026–2027 Special Emphasis Areas: For the 2026–2027 cycle, MRA seeks proposals in the
following areas, which are focused on current unmet clinical needs in melanoma. These areas are of particular interest, will receive special consideration, and can include pre-clinical, translational, clinical, and/or correlative studies:

  • Identifying new treatment strategies for rare melanoma subtypes, including acral, mucosal,
    uveal, or pediatric melanomas, with a focus on targets such as NF1, CRKL, B7-H3, YAP1,
    Gαq/11, GAB2, and NY-ESO-1
  • Understanding melanoma brain metastasis and leptomeningeal disease and identifying new
    treatment options
  • Identifying biomarkers of response/resistance to targeted and immune therapies
  • Identifying biomarkers to determine which patients with primary melanoma are at risk of
    progression